Misa Tanaka
YOU?
Author Swipe
View article: Potential Immune Microenvironment Biomarkers in Small Cell Lung Cancer: J-TAIL-2 Observational Study
Potential Immune Microenvironment Biomarkers in Small Cell Lung Cancer: J-TAIL-2 Observational Study Open
View article: Regulatory Stringency as a Competitive Tool for Financial Centres
Regulatory Stringency as a Competitive Tool for Financial Centres Open
View article: J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan Open
In J-TAIL-2, atezolizumab plus CE had efficacy in patients with ES-SCLC in clinical practice that was consistent with that in IMpower133. Taken together with the acceptable safety profile, these data support the use of atezolizumab plus CE…
View article: Incidence, Prediction, and Prevention of Fractures After Kidney Transplantation: A Systematic Review Protocol
Incidence, Prediction, and Prevention of Fractures After Kidney Transplantation: A Systematic Review Protocol Open
Background: Kidney transplant recipients are uniquely exposed to the disordered bone metabolism associated with chronic kidney disease beginning before transplantation followed by chronic corticosteroid use after transplantation. Previous …
View article: A Simple Flow Injection Analysis–Tandem Mass Spectrometry Method to Reduce False Positives of C5-Acylcarnitines Due to Pivaloylcarnitine Using Reference Ions
A Simple Flow Injection Analysis–Tandem Mass Spectrometry Method to Reduce False Positives of C5-Acylcarnitines Due to Pivaloylcarnitine Using Reference Ions Open
Flow injection analysis–tandem mass spectrometry (FIA-TMS) has been applied in a first-tier test of newborn screening (NBS). Although isovalerylcarnitine (i-C5), which is a diagnostic indicator of isovaleric acidemia (IVA), is isobaric wit…
View article: Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Open
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first‐line treatment for patients with unresectable MPM. Recently, prom…
View article: Does Bonus Cap Curb Risk Taking? An Experimental Study of Relative Performance Pay and Bonus Regulation
Does Bonus Cap Curb Risk Taking? An Experimental Study of Relative Performance Pay and Bonus Regulation Open
View article: Climate change challenges for central banks and financial regulators
Climate change challenges for central banks and financial regulators Open
The academic and policy debate regarding the role of central banks and financial regulators in addressing climate-related financial risks has rapidly expanded in recent years. This Perspective presents the key controversies and discusses p…
View article: Equity, Debt and Moral Hazard: The Optimal Structure of Banks’ Loss Absorbing Capacity
Equity, Debt and Moral Hazard: The Optimal Structure of Banks’ Loss Absorbing Capacity Open
View article: An Elusive Panacea? The Impact of the Regulatory Valuation Regime on Insurers' Investment Behaviour
An Elusive Panacea? The Impact of the Regulatory Valuation Regime on Insurers' Investment Behaviour Open
View article: How Do Bonus Cap and Malus Affect Risk and Effort Choice? Insight from a Lab Experiment
How Do Bonus Cap and Malus Affect Risk and Effort Choice? Insight from a Lab Experiment Open
View article: Optimal pay regulation for too-big-to-fail banks
Optimal pay regulation for too-big-to-fail banks Open
View article: Let's Talk About the Weather: The Impact of Climate Change on Central Banks
Let's Talk About the Weather: The Impact of Climate Change on Central Banks Open
View article: Bankers' Pay and Excessive Risk
Bankers' Pay and Excessive Risk Open
View article: Bank Leverage, Credit Traps and Credit Policies
Bank Leverage, Credit Traps and Credit Policies Open